As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Verrica Pharmaceuticals Inc. The largest reported stake is Paul B Manning's, at 49.9%. 8 filings are on record since August 14, 2025 (Schedule 13D/A, November 28, 2025).
Sell to companies like Verrica Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Armistice Capital, LLC · Percent: 4.99% · SCHEDULE 13G/A
- · Holder: Affinity Asset Advisors, LLC · Percent: 5.5% · SCHEDULE 13G/A
- · Holder: Caligan Partners LP · Percent: 9.99% · SCHEDULE 13D/A
- · Holder: Affinity Asset Advisors, LLC · Percent: 5.47% · SCHEDULE 13G
- · Holder: Paul B Manning · Percent: 49.9% · SCHEDULE 13D/A
Verrica Pharmaceuticals Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 49.9% | 8,056,031 | SCHEDULE 13D/A, 2025-11-28 | 2025-11-25 | |
| Caligan Partners LP | 9.99% | 6,503,054 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-26 |
| Affinity Asset Advisors, LLC | 5.5% | 884,172 | SCHEDULE 13G/A, 2026-01-29 | 2026-01-22 |
| Armistice Capital, LLC | 4.99% | 439,657 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Verrica Pharmaceuticals Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Verrica Pharmaceuticals Inc. and the records around it.
Verrica Pharmaceuticals Inc. elsewhere on the record
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- Paul B Manning also filed stake reports on 2 other companies: LIQUIDIA CORP (Aug 2026), CANDEL THERAPEUTICS, INC. (Mar 2026)
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
Watch Verrica Pharmaceuticals Inc.
Get an email when Verrica Pharmaceuticals Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Verrica Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Verrica Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Verrica Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Caligan Partners LP
On December 26, 2025, pursuant to the Purchase Agreement, the Issuer appointed Dr. Charles Frantzreb, a designee selected by Caligan, as a Class I member of the Board, effective immediately.Item 4 of the SCHEDULE 13D/A filed 2025-12-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 6.77% | SCHEDULE 13G/A |
| 2025-11-24 | Caligan Partners LP | 9.99% | SCHEDULE 13D |
| 2025-11-28 | Paul B Manning | 49.9% | SCHEDULE 13D/A |
| 2025-12-03 | Affinity Asset Advisors, LLC | 5.47% | SCHEDULE 13G |
| 2025-12-30 | Caligan Partners LP | 9.99% | SCHEDULE 13D/A |
| 2026-01-29 | Affinity Asset Advisors, LLC | 5.5% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
Questions about who owns Verrica Pharmaceuticals Inc.
Who owns Verrica Pharmaceuticals Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Verrica Pharmaceuticals Inc.: Paul B Manning (49.9%, Schedule 13D/A, filed 2025-11-28), Caligan Partners LP (9.99%, Schedule 13D/A, filed 2025-12-30) and Affinity Asset Advisors, LLC (5.5%, Schedule 13G/A, filed 2026-01-29).
Who are the largest shareholders of Verrica Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Verrica Pharmaceuticals Inc. on this page are Paul B Manning (49.9%), Caligan Partners LP (9.99%) and Affinity Asset Advisors, LLC (5.5%).
When did Paul B Manning buy into Verrica Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Paul B Manning on this page is the Schedule 13D/A, filed 2025-11-28, reporting 49.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Verrica Pharmaceuticals Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 10, 2025 | Form D, private offering | $50.02M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Verrica Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.